Design, synthesis and testing of amino-bicycloaryl based orally bioavailable thrombin inhibitors.
Replacement of the highly basic benzamidine moiety with moderate basic amino-bicycloaryl moieties in a series of thrombin inhibitors related to NAPAMP provided potent enzyme inhibition and significant improvements in membrane transport and oral bioavailability.